BRCA1 and metastatic neoplasm: In clinical practice, comprehensive genomic profiling—preferably using next-generation sequencing (NGS) panels covering BRCA1/2 and other HRR genes—should be conducted at the time of diagnosis of metastatic disease or upon progression to castration resistance.